the package insert of the medicine Cosopt.
the Treatment of elevated intraocular pressure in patients with ocular hypertension, open-angle glaucoma, glaucoma pseudo-esfoliativo and other secondary open-angle glaucomas when concomitant therapy is appropriate.
When should I not use?
bronchial Asthma or history of bronchial asthma or chronic obstructive pulmonary disease severe; sinus bradycardia, atrioventricular block of second or third degree, heart failure manifests, cardiogenic shock; hypersensitivity to any component of the product. These contraindications are based on the components and are not specific to the association.
How to use?
The dose is one drop of Cosopt in the(s) eye(s) affected(s) two times a day. When you replace Cosopt by the other(s) agent(s) eye(s) antiglaucomatoso(s), discontinue the other agent after proper administration in a day, starting to administer Cosopt on the next day. If another agent in the ophthalmic topic is being used, Cosopt and the other agent should be administered with an interval of at least 10 minutes. – Overdosage: no data are available regarding overdosage in humans by accidental ingestion or deliberate manipulation of Cosopt. There have been reports of overdosage accidental solution ophthalmic maleate timolol, which resulted in systemic effects similar to those observed with blockers (b-adrenergic systemic, such as, dizziness, headache, shortness of breath, bradycardia, bronchospasm and cardiac arrest. The most common signs and symptoms that may occur with overdosage of dorzolamide are electrolyte imbalance, development of state acidótico and, possibly, effects on the central nervous system. The treatment should be symptomatic and supportive. Serum electrolytes (particularly potassium) and pH in blood should be monitored. Studies have shown that timolol is not dialisado promptly.
What are the evils that can cause me?
In clinical studies, Cosopt was generally well tolerated; there was observed no adverse reactions peculiar to this combination. The adverse experiences have been limited to those reported previously with hydrochloride dorzolamide and/or maleate timolol. In general, the adverse experiences common were transient and did not require discontinuation of therapy. The adverse reactions related to the drug’s most frequent were: burning and acute pain of the eyes, altered taste, erosion corneal, congestion of the conjunctival, blurry vision, tearing and itching of the eye. Urolitíase has been reported rarely.
Warnings and Precautions
what should I know before using?
Reactions cardiopulmonary: the example of what occurs with other agents ophthalmic applied topically, this drug can be absorbed systemically. The timolol is a b-blocker. In this way, the same types of adverse reactions observed with the administration of systemic b-blockers may occur with the administration of topical. Due to the presence of maleate of timolol, cardiac failure should be adequately controlled before beginning therapy with Cosopt. In patients with a history of severe heart disease, signs of heart failure should be investigated and the frequency of the pulse should be checked. Reactions with respiratory and heart, including death due to bronchospasm in patients with asthma and rarely death in association with cardiac failure, have been reported after administration of solution ophthalmic maleate timolol.